Last updated on March 2019

Immune Disorder HSCT Protocol

Brief description of study

This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

Clinical Study Identifier: NCT01821781

Contact Investigators or Research Sites near you

Start Over

Washington University

Saint Louis, MO United States
  Connect »

Methodist Heathcare

San Antonio, TX United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.